Deutsche Bank Ag\ Provention Bio, Inc. Transaction History

Deutsche Bank Ag\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $117,464 - $424,449	17,532 Added 45.35%	56,188 $1.35 Million
Q4 2022 Feb 13, 2023	BUY	$4.52 - $10.57 $20,511 - $47,966	4,538 Added 13.3%	38,656 $408,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $20,562 - $33,691	5,995 Added 21.32%	34,118 $153,000
Q2 2022 Aug 11, 2022	SELL	$3.65 - $7.3 $8,621 - $17,242	-2,362 Reduced 7.75%	28,123 $113,000
Q1 2022 May 13, 2022	SELL	$3.4 - $7.88 $39,980 - $92,660	-11,759 Reduced 27.84%	30,485 $223,000
Q4 2021 Feb 11, 2022	SELL	$5.59 - $7.39 $208,931 - $276,208	-37,376 Reduced 46.94%	42,244 $237,000
Q3 2021 Nov 04, 2021	BUY	$5.66 - $8.33 $185,970 - $273,698	32,857 Added 70.26%	79,620 $509,000
Q2 2021 Aug 11, 2021	SELL	$6.71 - $11.04 $157,396 - $258,965	-23,457 Reduced 33.41%	46,763 $394,000
Q1 2021 May 13, 2021	BUY	$10.12 - $19.45 $276,316 - $531,062	27,304 Added 63.62%	70,220 $736,000
Q4 2020 Feb 16, 2021	BUY	$11.79 - $18.94 $167,264 - $268,701	14,187 Added 49.38%	42,916 $727,000
Q3 2020 Nov 12, 2020	BUY	$10.34 - $15.2 $46,147 - $67,837	4,463 Added 18.39%	28,729 $368,000
Q2 2020 Aug 13, 2020	BUY	$7.81 - $17.0 $189,517 - $412,522	24,266 New	24,266 $342,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.